Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Aclidinium bromide, Formoterol fumarate dihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Duaklir Genuair is This medicine contains two active ingredients called aclidinium and formoterol fumarate dihydrate. Both belong to a group of medicines called bronchodilators. Bronchodilators relax the muscles in your airways, which allows the airways to open more widely and helps you to breathe more easily. The Genuair inhaler delivers the active ingredients directly into your lungs as you breathe in. What Duaklir Genuair is used for Duaklir Genuair is used for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD), in which the airways and air sacs in the lungs become damaged or blocked. By opening the airways, the medicine helps relieve symptoms such as shortness of breath. Taking Duaklir Genuair regularly will reduce the effects of COPD on your everyday life. 2.
e Duaklir Genuair
Do not use Duaklir Genuair:
Confidential
Stop taking Duaklir Genuair and seek medical help immediately if you experience any of the following:
Duaklir Genuair
Confidential
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. –
–
The recommended dose is one inhalation in the morning and one inhalation in the evening. You can use Duaklir Genuair anytime before or after food or drink. The effects of Duaklir Genuair last for 12 hours; therefore, you should try to use Duaklir Genuair at the same time each morning and evening as this will ensure that there is always enough medicine in your body to help you breathe more easily throughout the day and night. Taking your medicine at regular times will also help you to remember to use it. The recommended dose can be used for elderly patients and for patients with kidney or liver problems. No dose adjustments are necessary in these patients. Duaklir Genuair is for inhalation use. Instructions for use: Refer to the Instructions for Use at the end of this leaflet for instructions on how to use the Genuair inhaler. If you are not sure of how to use Duaklir Genuair, contact your doctor or pharmacist.
COPD is a long-term disease; therefore, Duaklir Genuair is for long-term use. The medicine must be used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced. If you use more Duaklir Genuair than you should If you think you may have used more Duaklir Genuair than you should, you are more likely to experience some of its side effects, such as blurred vision, dry mouth, feeling sick, shaking/tremor, headache, palpitations or an increase in blood pressure, therefore you must immediately contact your doctor or go to the nearest emergency unit. Show the packaging of Duaklir Genuair. Medical attention may be needed. If you forget to use Duaklir Genuair If you forget a dose of Duaklir Genuair, just take it as soon as possible and take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose. If you stop using Duaklir Genuair This medicine is for long-term use. If you want to stop treatment, first talk to your doctor, as your symptoms may worsen. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop using the medicine and contact your doctor immediately if you: –
develop swelling of the face, throat, lips or tongue (with or without difficulty breathing or swallowing), severe itchy bumps on the skin (hives) as these may be symptoms of an allergic reaction. Frequency of this reaction cannot be estimated from the available data. develop tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. These may be signs of a condition called "paradoxical bronchospasm", which is an excessive and prolonged contraction of the airway muscles immediately following treatment with a bronchodilator. This reaction may rarely occur (may affect up to 1 in 1,000 people).
Some side effects may be serious: if you get any of these side effects, tell your doctor immediately. Uncommon (may affect up to 1 in 100 people)
Confidential
–
Tiredness, increased thirst and/or a need to pass urine more frequently than usual, as these may be signs of an increase in the amount of sugar in your blood Palpitations, as these may be a sign of an unusually fast heart beat or an abnormal heart rhythm
Rare (may affect up to 1 in 1,000 people)
Duaklir Genuair
Confidential
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the inhaler label, carton and inhaler bag after "EXP". The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Keep the Genuair inhaler protected inside the sealed bag until the administration period starts. To be used within 60 days of opening the bag. Do not use Duaklir Genuair if you notice that the pack is damaged or shows signs of tampering. After you have taken the last dose, the inhaler has to be disposed of. Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Duaklir Genuair contains The active substances are aclidinium and formoterol fumarate dihydrate. Each delivered dose (the dose leaving the mouthpiece) contains 396 micrograms aclidinium bromide equivalent to 340 micrograms of aclidinium and 11.8 micrograms of formoterol fumarate dihydrate. The other ingredient is lactose monohydrate (see end of section 2 under 'Duaklir Genuair contains lactose' for more information). What Duaklir Genuair looks like and contents of the pack Duaklir Genuair is a white or almost white inhalation powder. The Genuair inhaler is a white device fitted with an integral dose indicator and an orange dosage button. The mouthpiece is covered with a removable orange protective cap. It is supplied in a sealed protective aluminium bag containing a desiccant sachet. After removing the inhaler from the bag, the bag and desiccant sachet should be thrown away. Pack sizes supplied: Carton containing 1 inhaler with 30 doses. Carton containing 1 inhaler with 60 doses. Carton containing 3 inhalers each with 60 doses. Not all pack sizes may be marketed. Marketing Authorisation Holder Azurity Pharmaceuticals Ireland Ltd. The Observatory 7-11 Sir John Rogerson's Quay Dublin 2, D02 VC42 Ireland Manufacturer Industrias Farmacéuticas Almirall, S.A. Ctra. de Martorell 41-61 08740 Sant Andreu de la Barca, Barcelona Spain This leaflet was last revised in July 2026.
Confidential
Other sources of information
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 08004334029 (UK only) Please be ready to give the following information: Product name Duaklir Genuair 340 micrograms / 12 micrograms inhalation powder
Reference number PL 60277/0003
This is a service provided by the Royal National Institute of the Blind. Instructions for Use This section contains information on how to use your Genuair inhaler. It is important that you read this information as the Genuair may work differently from inhalers you have used previously. If you have any questions about how to use your inhaler, please ask your doctor, pharmacist or nurse for assistance. The Instructions for Use is divided into the following sections:
Confidential
Control window Green = inhaler ready to use
Dose indicator
Protective Cap
Orange button
Control window Red = confirms correct inhalation
Mouthpiece
Figure A Before use: a) Before first use, tear open the sealed bag and remove the inhaler. Throw away the bag and the desiccant. b) Do not press the orange button until you are ready to take a dose. c) Pull off the cap by lightly squeezing the arrows marked on each side (Figure B).
Squeeze here and pull
Figure B STEP 1: Prepare your dose 1.1 Look in the opening of the mouthpiece and make sure nothing is blocking it (Figure C). 1.2 Look at the control window (should be red, Figure C).
Confidential
RED
Check mouthpiece opening
Figure C 1.3 Hold the inhaler horizontally with the mouthpiece facing you and the orange button on top (Figure D).
Figure D 1.4 Press the orange button all the way down to load your dose (Figure E). When you press the button all the way down, the control window changes from red to green. Make sure the orange button is on top. Do not tilt. 1.5 Release the orange button (Figure F). Make sure you release the button so the inhaler can work correctly.
Figure E
Figure F
Confidential
Stop and Check: 1.6 Make sure the control window is now green (Figure G). Your medicine is ready to be inhaled. Go to 'STEP 2: Inhale your medicine'. GREEN
Figure G What to do if the control window is still red after pressing the button (Figure H).
Figure H The dose is not prepared. Go back to 'STEP 1 Prepare your dose' and repeat steps 1.1 to 1.6. STEP 2: Inhale your medicine Read steps 2.1 to 2.7 fully before use. Do not tilt. 2.1 Hold the inhaler away from your mouth, and breathe out completely. Never breathe out into the inhaler (Figure I).
Figure I
Confidential
2.2 Hold your head upright, put the mouthpiece between your lips, and close your lips tightly around it (Figure J). Do not hold the orange button down while inhaling.
Figure J 2.3 Take a strong, deep breath through your mouth. Keep breathing in for as long as possible. A 'click' will let you know that you are inhaling correctly. Keep breathing in as long as possible after you hear the 'click'. Some patients may not hear the 'click'. Use the control window to ensure you have inhaled correctly. 2.4 Take the inhaler out of your mouth. 2.5 Hold your breath for as long as possible. 2.6 Slowly breathe out away from the inhaler. Some patients may experience a grainy sensation in their mouth, or a slightly sweet or bitter taste. Do not take an extra dose even if you do not taste or feel anything after inhaling. Stop and Check: 2.7 Make sure the control window is now red (Figure K). This means you have inhaled your medicine correctly. RED
Figure K
Confidential
What to do if the control window is still green after inhalation (Figure L).
Figure L This means you have not inhaled your medicine correctly. Go back to 'STEP 2 Inhale your medicine' and repeat steps 2.1 to 2.7. If the control window still does not change to red, you may have forgotten to release the orange button before inhaling, or you may not have inhaled strongly enough. If this happens, try again. Make sure you have released the orange button, and you have breathed out completely. Then take a strong, deep breath through the mouthpiece. Please contact your doctor if the control window is still green after repeated attempts. Push the protective cap back onto the mouthpiece after each use (Figure M), to prevent contamination of the inhaler with dust or other materials. You should discard your inhaler if you lose the cap.
Figure M Additional information What should you do if you accidently prepare a dose? Store your inhaler with the protective cap in place until it is time to inhale your medicine, then remove the cap and start at Step 1.6. How does the dose indicator work?
Confidential
Red band
Figure N How do you know that your inhaler is empty? When the orange button will not return to its full upper position and is locked in a middle position, you have reached the last dose (Figure O). Even though the orange button is locked, your last dose may still be inhaled. After that, the inhaler cannot be used again and you should start using a new inhaler.
Locked
Figure O How should you clean the inhaler? NEVER use water to clean the inhaler, as this may damage your medicine. If you wish to clean your inhaler, just wipe the outside of the mouthpiece with a dry tissue or paper towel.
Confidential
Duaklir Genuair 340 micrograms /12 micrograms inhalation powder comes as inhaler containing 340mcg / 12mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Duaklir Genuair 340 micrograms /12 micrograms inhalation powder is aclidinium bromide, formoterol fumarate dihydrate.
This leaflet reproduces the patient information leaflet approved for Duaklir Genuair 340 micrograms /12 micrograms inhalation powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Posology
The recommended dose is one inhalation twice daily.
If a dose is missed, it should be taken as soon as possible and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.
Elderly
No dose adjustments are required in elderly patients (see section 5.2).
Renal impairment
No dose adjustments are required in patients with renal impairment (see section 5.2).
Hepatic impairment
No dose adjustments are required in patients with hepatic impairment (see section 5.2).
Paediatric population
There is no relevant use of Duaklir Genuair in children and adolescents (under 18 years of age) for the indication of COPD.
Method of administration
For inhalation use.
Patients should be instructed on how to administer the product correctly as the Genuair inhaler may work differently from inhalers the patients may have used previously. It is important to instruct the patients to read the Instructions for Use in the Package Leaflet.
Before first use, the sealed bag should be teared open, and the inhaler removed. The bag and the desiccant should be thrown away.
For instructions for use, see section 6.6.
Hypersensitivity to the active substances or to the excipient listed in section 6.1.
Asthma
Duaklir Genuair should not be used in asthma; clinical studies of Duaklir Genuair in asthma have not been conducted.
Paradoxical bronchospasm
In clinical studies, paradoxical bronchospasm was not observed with Duaklir Genuair at its recommended dose. However, paradoxical bronchospasm has been observed with other inhalation therapies. If this occurs, medicinal product should be stopped and other treatment will be considered.
Not for acute use
Duaklir Genuair is not indicated for the treatment of acute episodes of bronchospasm.
Cardiovascular effects
β2-adrenergic agonists may produce increases in pulse rate and blood pressure, electrocardiogram (ECG) changes such as T wave flattening, ST segment depression and prolongation of the QTc-interval in some patients. In case such effects occur, treatment may need to be discontinued. Long-acting β2-adrenergic agonists should be used with caution in patients with history of or known prolongation of the QTc-interval or treated with medicinal products affecting the QTc interval (see section 4.5).
Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia were seen after the administration of Duaklir Genuair (see section 4.8). Therefore, Duaklir Genuair should be used with caution in patients with cardiac arrhythmias, a history of cardiac arrhythmias or with risk factors for cardiac arrhythmias.
Systemic effects
Duaklir Genuair should be used with caution in patients with severe cardiovascular disorders, convulsive disorders, thyrotoxicosis and phaeochromocytoma.
Metabolic effects of hyperglycaemia and hypokalaemia may be observed with high doses of β2‑adrenergic agonists. In Phase III clinical studies, the frequency of notable increases in blood glucose with Duaklir Genuair was low (0.1%) and similar to placebo. Hypokalaemia is usually transient, not requiring supplementation. In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (see section 4.5). Hypokalaemia increases susceptibility to cardiac arrhythmias.
Due to its anticholinergic activity, Duaklir Genuair should be used with caution in patients with symptomatic prostatic hyperplasia, urinary retention or narrow-angle glaucoma (even though direct contact of the product with the eyes is very unlikely). Dry mouth, which has been observed with anticholinergic treatment, may in the long term be associated with dental caries.
Lactose content
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
COPD medicinal products
Co-administration of Duaklir Genuair with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended.
Although no formal in vivo drug interaction studies have been performed with Duaklir Genuair, it has been used concomitantly with other COPD medicinal products including short-acting β2-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids without clinical evidence of drug interactions.
Hypokalaemic treatment
Concomitant treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of β2-adrenergic agonists, therefore caution is advised in their concomitant use (see section 4.4).
β-adrenergic blockers
β-adrenergic blockers may weaken or antagonise the effect of β2-adrenergic agonists. If β-adrenergic blockers are required (including eye drops), cardioselective beta-adrenergic blockers are preferred, although they should also be administered with caution.
Other pharmacodynamic interactions
Duaklir Genuair should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval such as monoamine oxidase inhibitors, tricyclic antidepressants, antihistamines or macrolides because the action of formoterol, a component of Duaklir Genuair, on the cardiovascular system may be potentiated by these medicinal products. Medicinal products that are known to prolong the QTc interval are associated with an increased risk of ventricular arrhythmias.
Metabolic interactions
In vitro studies have shown that aclidinium or its metabolites at the therapeutic dose are not expected to cause interactions with P-glycoprotein (P-gp) substrate drugs or drugs metabolised by cytochrome P450 (CYP450) enzymes and esterases. Formoterol does not inhibit the CYP450 enzymes at therapeutically relevant concentrations (see section 5.2).
Pregnancy
There are no data available on the use of Duaklir Genuair in pregnant women.
Studies in animals have shown foetotoxicity only at dose levels much higher than the maximum human exposure to aclidinium and adverse effects in reproduction studies with formoterol at very high systemic exposure levels (see section 5.3).
Duaklir Genuair should only be used during pregnancy if the expected benefits outweigh the potential risks.
Breast-feeding
It is unknown whether aclidinium (and/or its metabolites) or formoterol are excreted in human milk. As studies in rats have shown excretion of small amounts of aclidinium (and/or its metabolites) and formoterol into milk, the use of Duaklir Genuair by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant.
Fertility
Studies in rats have shown slight reductions in fertility only at dose levels much higher than the maximum human exposure to aclidinium and formoterol (see section 5.3). Nevertheless, it is considered unlikely that Duaklir Genuair administered at the recommended dose will affect fertility in humans.
Duaklir Genuair has no or negligible influence on the ability to drive and use machines. The occurrence of blurred vision or dizziness may influence the ability to drive or to use machines.
The presentation of the safety profile is based on the experience with Duaklir Genuair and the individual components.
Summary of the safety profile
The safety experience with Duaklir Genuair comprised exposure in clinical trials at the recommended therapeutic dose for up to 12 months, and in post-marketing experience.
Adverse reactions associated with Duaklir Genuair were similar to those of the individual components. As Duaklir Genuair contains aclidinium and formoterol, the type and severity of adverse reactions associated with each of the components may be expected with Duaklir Genuair.
The most frequently reported adverse reactions with Duaklir Genuair were nasopharyngitis (7.9%) and headache (6.8%).
Tabulated summary of adverse reactions
The Duaklir Genuair clinical development programme was conducted in patients with moderate or severe COPD. A total of 1222 patients were treated with Duaklir Genuair 340 micrograms /12 micrograms. The frequencies assigned to the adverse reactions are based on crude incidence rates observed with Duaklir Genuair 340 micrograms /12 micrograms in the pooled analysis of randomised, placebo-controlled Phase III clinical studies of at least six months duration, or on experience with individual components or on post-marketing study results.
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).
System organ class
Preferred term
Frequency
Infectious and infestations
NasopharyngitisUrinary tract infectionSinusitisTooth abscess
Common
Immune system disorders
Hypersensitivity
Rare
Angioedema
Anaphylactic reaction
Not known
Metabolism and nutrition disorders
Hypokalaemia
Uncommon
Hyperglycaemia
Uncommon
Psychiatric disorders
InsomniaAnxiety
Common
Agitation
Uncommon
Nervous system disorders
Headache
Dizziness
Tremor
Common
Dysgeusia
Uncommon
Eye disorders
Blurred vision
Uncommon
Cardiac disorders
Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia
TachycardiaElectrocardiogram QTc prolongedPalpitations
Angina pectoris
Uncommon
Respiratory, Thoracic and mediastinal disorders
Cough
Common
Dysphonia
Throat irritation
Uncommon
Bronchospasm, including paradoxical
Rare
Gastrointestinal disorders
Diarrhoea
Nausea
Dry mouth
Common
Stomatitis
Uncommon
Skin and subcutaneous tissue disorders
Rash
Pruritus
Uncommon
Musculoskeletal and connective tissue disorders
Myalgia
Muscle spasms
Common
Renal and urinary disorders
Urinary retention
Uncommon
Investigations
Blood creatine phosphokinase increased
Common
Blood pressure increased
Uncommon
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There is limited evidence on the management of overdose with Duaklir Genuair. High doses of Duaklir Genuair may lead to exaggerated anticholinergic and/or β2-adrenergic signs and symptoms; the most frequent of which include blurred vision, dry mouth, nausea, muscle spasm, tremor, headache, palpitations and hypertension.
Duaklir Genuair should be discontinued in case of overdose. Supportive and symptomatic treatment is indicated.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Aclidinium bromide, Formoterol fumarate dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Duaklir Genuair 340 micrograms /12 micrograms inhalation powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.